JP2018510898A5 - - Google Patents

Download PDF

Info

Publication number
JP2018510898A5
JP2018510898A5 JP2017553076A JP2017553076A JP2018510898A5 JP 2018510898 A5 JP2018510898 A5 JP 2018510898A5 JP 2017553076 A JP2017553076 A JP 2017553076A JP 2017553076 A JP2017553076 A JP 2017553076A JP 2018510898 A5 JP2018510898 A5 JP 2018510898A5
Authority
JP
Japan
Prior art keywords
amisulpride
unit dose
antiemetic
kit
acute phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017553076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510898A (ja
JP6812360B2 (ja
Filing date
Publication date
Priority claimed from GBGB1506116.1A external-priority patent/GB201506116D0/en
Application filed filed Critical
Publication of JP2018510898A publication Critical patent/JP2018510898A/ja
Publication of JP2018510898A5 publication Critical patent/JP2018510898A5/ja
Application granted granted Critical
Publication of JP6812360B2 publication Critical patent/JP6812360B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017553076A 2015-04-10 2016-04-11 嘔気嘔吐を治療するためのアミスルプリドと他の制吐薬との併用 Active JP6812360B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1506116.1A GB201506116D0 (en) 2015-04-10 2015-04-10 Kit and combination therapy for nausea and vomiting
GB1506116.1 2015-04-10
PCT/GB2016/050998 WO2016162695A1 (en) 2015-04-10 2016-04-11 Combinations of amisulpride and another anti-emetic for treating nausea and vomiting

Publications (3)

Publication Number Publication Date
JP2018510898A JP2018510898A (ja) 2018-04-19
JP2018510898A5 true JP2018510898A5 (https=) 2019-04-18
JP6812360B2 JP6812360B2 (ja) 2021-01-13

Family

ID=53333601

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017553076A Active JP6812360B2 (ja) 2015-04-10 2016-04-11 嘔気嘔吐を治療するためのアミスルプリドと他の制吐薬との併用

Country Status (22)

Country Link
US (1) US10322106B2 (https=)
EP (1) EP3280392B1 (https=)
JP (1) JP6812360B2 (https=)
KR (2) KR20240125705A (https=)
CN (1) CN107872975A (https=)
AU (1) AU2016246104B2 (https=)
CA (1) CA2982251C (https=)
CY (1) CY1124184T1 (https=)
DK (1) DK3280392T3 (https=)
ES (1) ES2866933T3 (https=)
GB (1) GB201506116D0 (https=)
HR (1) HRP20210624T1 (https=)
HU (1) HUE054165T2 (https=)
IL (2) IL295650A (https=)
LT (1) LT3280392T (https=)
MX (1) MX388735B (https=)
PL (1) PL3280392T3 (https=)
PT (1) PT3280392T (https=)
RS (1) RS61760B1 (https=)
SI (1) SI3280392T1 (https=)
SM (1) SMT202100216T1 (https=)
WO (1) WO2016162695A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CA3084953A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
AU2018378348B2 (en) 2017-12-05 2024-09-19 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
JP2026501171A (ja) 2022-12-15 2026-01-14 ガシャーブラム・バイオ・インコーポレイテッド Glp-1アゴニスト活性を有する化合物の塩および固体形態
JP2026501285A (ja) 2022-12-22 2026-01-14 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式glp-1アゴニスト
CN120693338A (zh) 2022-12-22 2025-09-23 加舒布鲁姆生物公司 杂环的glp-1激动剂
AU2024222719A1 (en) 2023-02-16 2025-08-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20250019389A1 (en) 2023-06-30 2025-01-16 Gasherbrum Bio, Inc. Heterocyclic agonists
WO2025015269A1 (en) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Compounds, compositions, and methods
WO2025015268A1 (en) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Modulators of calcitonin receptor and/or amylin receptor activity
WO2025045208A1 (en) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss
WO2026041075A1 (en) 2024-08-21 2026-02-26 Gasherbrum Bio, Inc. Gpl-1 agonists
WO2026051998A1 (en) 2024-09-04 2026-03-12 Aconcagua Bio, Inc. Compounds, compositions, and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201003962D0 (en) 2010-03-10 2010-04-21 Tangentix Ltd Multimedia content delivery system
GB201004020D0 (en) * 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
US20150018360A1 (en) * 2011-09-13 2015-01-15 Biomed Valley Discoveries, Inc. Compositions and methods for treating metabolic disorders

Similar Documents

Publication Publication Date Title
JP2018510898A5 (https=)
KR102711661B1 (ko) 구역과 구토를 치료하기 위한 아미설프리드 및 추가의 구토 방지제의 병용
JP2016106150A5 (https=)
JP2012193216A5 (https=)
HRP20180301T1 (hr) Postupci liječenja psorijaze uporabom il-17 antagonista
JP2013516493A5 (https=)
JP2016532516A5 (https=)
JP2018530578A5 (https=)
JP2018138596A5 (https=)
Ortiz et al. The combination of naproxen and citral reduces nociception and gastric damage in rats
JP2019511506A5 (https=)
JP2016515137A5 (https=)
RU2019101226A (ru) Ингибиторы wnt для применения при лечении фиброза
FI3590960T3 (fi) Perifeeristen hermojen IgG-stimuloitu remyelinaatio
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
JP2014508174A5 (https=)
JP2020506209A5 (https=)
JP2015510945A5 (https=)
SI2686002T1 (en) A method for reducing influenza-like symptoms associated with intramuscular delivery of interferon by the rapid titration-enhancing regimen
RU2013126798A (ru) Комбинированная терапия дексаметазоном
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
JP2013542262A5 (https=)
RU2018144248A (ru) Схемы дозирования вортиоксетина для быстрого появления антидепрессивного эффекта
WO2016077565A3 (en) Methods for chronic pain management and treatment using hcg
JP2017530142A5 (https=)